Artesunate + Sulfadoxine-Pyrimethamine — Competitive Intelligence Brief

Artesunate + Sulfadoxine-Pyrimethamine (Artesunate + Sulfadoxine-Pyrimethamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium falciparum (multiple targets: artemisinin-induced oxidative stress; dihydrofolate reductase; dihydropteroate synthase) Infectious Disease Small molecule

Target snapshot

Artesunate + Sulfadoxine-Pyrimethamine (Artesunate + Sulfadoxine-Pyrimethamine) — Sanofi. Artesunate kills malaria parasites by generating reactive oxygen species, while sulfadoxine-pyrimethamine inhibits folate synthesis in the parasite, providing synergistic antimalarial activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artesunate + Sulfadoxine-Pyrimethamine TARGET	Artesunate + Sulfadoxine-Pyrimethamine	Sanofi	marketed	Antimalarial combination	Plasmodium falciparum (multiple targets: artemisinin-induced oxidative stress; dihydrofolate reductase; dihydropteroate synthase)
Amodiaquine plus sulphadoxine-pyrimethamine combination	Amodiaquine plus sulphadoxine-pyrimethamine combination	Centre for Global Health Research, Ghana	marketed	Antimalarial combination	Plasmodium dihydrofolate reductase, dihydropteroate synthase, and hemozoin formation
Artesunate plus Amodiaquine	Artesunate plus Amodiaquine	Bernhard Nocht Institute for Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis)
Coadministered Artesunate plus Amodiaquine	Coadministered Artesunate plus Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination therapy	Plasmodium falciparum heme metabolism and protein synthesis
Artemether, Lumefantrine Drug Combination	Artemether, Lumefantrine Drug Combination	University of Yaounde 1	marketed	Antimalarial combination	Plasmodium falciparum heme and mitochondrial function
SP-IPTp	SP-IPTp	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum dihydrofolate reductase (sulfadoxine-pyrimethamine); hemozoin formation (piperaquine)
artesunate and mefloquine	artesunate and mefloquine	Mepha Ltd.	marketed	Antimalarial combination	Plasmodium falciparum heme iron (artesunate); parasite digestive vacuole and mitochondria (mefloquine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class